Literature DB >> 12422941

An exploratory study: the use of paroxetine for methamphetamine craving.

Melissa P Piasecki1, Gerri M Steinagel, Ole J Thienhaus, Barbara S Kohlenberg.   

Abstract

Methamphetamine abuse and dependence are growing problems nationally and worldwide. There are currently no effective pharmocologic treatments. Animal studies with SSRI's suggest that serotonergic modulation alters methamphetamine's behavioral effects. This exploratory study is a trial of the effects of the SSRI paroxetine versus placebo (in a double blind design) on craving and use in a population of methamphetamine users. Many subjects dropped out of the study, but those in active treatment who completed the eight week trial had a decrease in methamphetamine craving compared to the placebo treatment as measured by the OCDS modified for use in this population. Statistical analyses were not performed due to the low number of subjects. The preliminary data suggest that serotonergic agents may play a role in the effective treatment of methamphetamine abuse and dependence within the context of other effective behavioral interventions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12422941     DOI: 10.1080/02791072.2002.10399967

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  13 in total

1.  Cytochrome P450-2D6 extensive metabolizers are more vulnerable to methamphetamine-associated neurocognitive impairment: preliminary findings.

Authors:  Mariana Cherner; Chad Bousman; Ian Everall; Daniel Barron; Scott Letendre; Florin Vaida; J Hampton Atkinson; Robert Heaton; Igor Grant
Journal:  J Int Neuropsychol Soc       Date:  2010-08-23       Impact factor: 2.892

2.  Attenuated beta endorphin response to acute stress is associated with smoking relapse.

Authors:  Darcy Shaw; Mustafa al'Absi
Journal:  Pharmacol Biochem Behav       Date:  2008-04-03       Impact factor: 3.533

3.  Investigating Methamphetamine Craving Using the Extinction-Reinstatement Model in the Rat.

Authors:  Peter R Kufahl; M Foster Olive
Journal:  J Addict Res Ther       Date:  2011-11-15

4.  Sertraline delays relapse in recently abstinent cocaine-dependent patients with depressive symptoms.

Authors:  Alison Oliveto; James Poling; Michael J Mancino; D Keith Williams; Jeff Thostenson; Rhonda Pruzinsky; Kishorchandra Gonsai; Mehmet Sofuoglu; Gerardo Gonzalez; Shanti Tripathi; Thomas R Kosten
Journal:  Addiction       Date:  2011-10-10       Impact factor: 6.526

Review 5.  Pharmacological approaches to methamphetamine dependence: a focused review.

Authors:  Laurent Karila; Aviv Weinstein; Henri-Jean Aubin; Amine Benyamina; Michel Reynaud; Steven L Batki
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

Review 6.  Utility of preclinical drug versus food choice procedures to evaluate candidate medications for methamphetamine use disorder.

Authors:  Matthew L Banks
Journal:  Ann N Y Acad Sci       Date:  2016-12-09       Impact factor: 5.691

7.  Poor response to sertraline in methamphetamine dependence is associated with sustained craving for methamphetamine.

Authors:  Todd Zorick; Catherine A Sugar; Gerhard Hellemann; Steve Shoptaw; Edythe D London
Journal:  Drug Alcohol Depend       Date:  2011-05-17       Impact factor: 4.492

Review 8.  Pharmacotherapy of amphetamine-type stimulant dependence: an update.

Authors:  Matthew Brensilver; Keith G Heinzerling; Steven Shoptaw
Journal:  Drug Alcohol Rev       Date:  2013-04-25

Review 9.  Biological treatments for amfetamine dependence : recent progress.

Authors:  Kevin P Hill; Mehmet Sofuoglu
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

10.  Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder.

Authors:  Walter Ling; Linda Chang; Maureen Hillhouse; Alfonso Ang; Joan Striebel; Jessica Jenkins; Jasmin Hernandez; Mary Olaer; Larissa Mooney; Susan Reed; Erin Fukaya; Shannon Kogachi; Daniel Alicata; Nataliya Holmes; Asher Esagoff
Journal:  Addiction       Date:  2014-07-08       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.